Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 25.95
-0.83 (-3.10%)
At close: Aug 21, 2026
SHA:688443 Revenue
Chongqing Genrix Biopharmaceutical had revenue of 67.25M CNY in the quarter ending March 31, 2026, with 233.63% growth. This brings the company's revenue in the last twelve months to 277.82M, up 452.93% year-over-year. In the year 2025, Chongqing Genrix Biopharmaceutical had annual revenue of 230.73M with 666.66% growth.
Revenue (ttm)
277.82M
Revenue Growth
+452.93%
P/S Ratio
34.25
Revenue / Employee
282.34K
Employees
984
Market Cap
9.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 230.73M | 200.63M | 666.66% |
| Dec 31, 2024 | 30.09M | 28.88M | 2,384.11% |
| Dec 31, 2023 | 1.21M | 736.26K | 154.92% |
| Dec 31, 2022 | 475.24K | -38.72M | -98.79% |
| Dec 31, 2021 | 39.19M | 38.10M | 3,502.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.60B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.93B |
| Aurisco Pharmaceutical | 1.68B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Liaoning Chengda Biotechnology | 1.31B |
| Bio-Thera Solutions | 980.25M |